In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

Ewing Sarcoma is a Highly Metastatic Form of Sarcoma and the Second Most Prevalent Primary ... difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), announced ...

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

Good morning, and welcome to the Wave Life Sciences Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen only mode. As a reminder, this call is being ...

If the Superior Court rejects the application to raise it to the Supreme Court, GSK and the other defendants ... and it was also sold in generic form by several other producers.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced ...

A spokesman for AZ told Pharmaphorum that the CRL “states that more clinical data are required to support the application ... The FDA has form on this issue, rejecting GSK’s IL-5 inhibitor ...

Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highli ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...